Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4682 |
Name | extrahepatic bile duct carcinoma |
Definition | A cholangiocarcinoma that arises from the extrahepatic bile ducts. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer hepatobiliary system cancer biliary tract cancer bile duct cancer bile duct carcinoma bile duct adenocarcinoma cholangiocarcinoma extrahepatic bile duct carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
MLH1 negative | Dostarlimab-gxly | extrahepatic bile duct carcinoma | sensitive | detail... |
MSH6 negative | Dostarlimab-gxly | extrahepatic bile duct carcinoma | sensitive | detail... |
MSH6 negative | Pembrolizumab | extrahepatic bile duct carcinoma | sensitive | detail... |
MLH1 negative | Pembrolizumab | extrahepatic bile duct carcinoma | sensitive | detail... |
RET fusion | Pralsetinib | extrahepatic bile duct carcinoma | sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | extrahepatic bile duct carcinoma | sensitive | detail... |
RET fusion | Selpercatinib | extrahepatic bile duct carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02834013 | Phase 0 | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
NCT04203160 | Phase Ib/II | Cisplatin + Gemcitabine Cisplatin + CPI-613 + Gemcitabine | Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) | Completed | USA | 0 |
NCT04907851 | Phase II | Denosumab + RXC004 Denosumab + Pembrolizumab + RXC004 | A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (KEYNOTE-E86) | Completed | GBR | AUS | 0 |
NCT05239169 | Phase II | Capecitabine + Durvalumab + Tremelimumab Durvalumab + Tremelimumab | Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | Active, not recruiting | DEU | 0 |
NCT05564403 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin | Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) | Recruiting | USA | 0 |
NCT06274879 | Phase II | Cisplatin + Durvalumab + Gemcitabine | Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer (Ablatio) | Not yet recruiting | CHE | 0 |
NCT06546969 | Phase I | Cisplatin + Durvalumab + Gemcitabine | Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer | Recruiting | USA | 0 |